サンプル依頼リスト カート
  • English
  • Korean
表紙：免疫グロブリンの世界市場-2023年～2030年
市場調査レポート
商品コード
1374846

免疫グロブリンの世界市場-2023年～2030年

Global Immunoglobulin Market - 2023-2030

出版日
ページ情報
英文 187 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
免疫グロブリンの世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

抗体としても知られる免疫グロブリン（Ig）は、形質細胞によって産生される糖タンパク質です。B細胞は、細菌タンパク質などの特異的免疫原によって、細菌、ウイルス、真菌、寄生虫、細胞抗原、化学物質、合成物質に対する体液性免疫応答に関与するタンパク質産生細胞である形質細胞に分化するよう指示されます。免疫原または抗原は、Bリンパ球の細胞表面にあるB細胞レセプターと反応します。B細胞を刺激した免疫原に特異性の高い抗体の合成を刺激するために、転写因子の活性化を指示するシグナルが産生されます。

さらに、形質細胞によって産生される様々な免疫グロブリンはアイソタイプによって分類され、それぞれは主に構造の多様性によって機能と抗原反応が異なります。胎盤哺乳類で同定されている5つの主要な抗体クラスは、IgA、IgD、IgE、IgG、IgMです。この分類は、抗体重鎖の定常領域におけるアミノ酸配列の相違に基づいています。IgGとIgAは、さらにアミノ酸重鎖配列のわずかな違いに基づいてサブクラスに分類されます。これらは多くの自己免疫疾患やその他の慢性疾患の治療に使用されています。

市場力学：促進要因

革新的な免疫グロブリンに対する需要の増加

革新的な免疫グロブリンに対する需要の増加が、予測期間を通じて市場を牽引するとみられます。革新的免疫グロブリンは、主にさまざまな種類の疾患を治療するために設計されており、代替的または補完的な治療オプションを提供することによって、さまざまな疾患の管理および治療に関連するアンメットニーズに対処することを目的としています。FDA承認などの規制当局による承認も増加しており、免疫グロブリンの採用がさらに進んでいます。

例えば、2023年5月19日、アッヴィは、米国食品医薬品局（FDA）の承認を取得しました。EPKINLYTM（epcoritamab-bysp）は、再発または難治性（R/R）のびまん性大細胞型B細胞リンパ腫（DLBCL）、特定不能（NOS）（低悪性度リンパ腫から発生したDLBCLを含む）、および高悪性度B細胞リンパ腫（HGBL）の成人患者に対する治療薬として、2ライン以上の全身療法後の最初で唯一のT細胞関与二重特異性抗体として、米国食品医薬品局（FDA）から承認されました。EPKINLYは、Genmab社独自のDuoBody技術を用いて創製されたIgG1二重特異性抗体です。

さらに、免疫グロブリンは従来、原発性免疫不全症や自己免疫疾患などの疾患に使用されてきました。しかし、研究者や製薬会社は、免疫グロブリンを用いることで、より幅広い疾患の治療や診断の可能性を探ることに注力しています。

例えば、サービングサイエンスの世界的リーダーであるサーモフィッシャーサイエンティフィック社は、2023年8月24日、IVDR認証を取得し、EXENTソリューションを発売しました。EXENTソリューションは、多発性骨髄腫を含むモノクローナル・ガモパチー患者の診断と評価を変革するために設計された、完全に統合された自動質量分析システムです。この分析装置は、IgG、IgA、およびIgMを測定および定量するための高感度かつ特異的な免疫測定法であるEXENT免疫グロブリンアイソタイプ（GAM）免疫測定法と組み合わされます。

さらに、2022年3月29日、サノフィはIGMバイオサイエンシズと提携し、6種類の免疫グロブリンM（IgM）抗体アゴニストを創製、開発、製造、商業化しました。

さらに、免疫不全やその他の免疫関連疾患の有病率の増加、FDA承認の増加、臨床試験の増加、認知度の向上、新規製品開発の進展などが、予測期間中に市場を牽引すると予想される要因です。

阻害要因

輸血関連急性肺障害（TRALI）、急性腎不全、IgEやIgA対抗IgG抗体に対するアナフィラキシー、不整脈、無菌性髄膜炎、関節炎、肝炎、胸水、その他の皮膚症状など、免疫グロブリンの重篤かつ稀な副作用などの要因は、市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 革新的な免疫グロブリンに対する需要の増加
    • 抑制要因
      • 免疫グロブリンの重篤な副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • アンメットニーズ
  • 特許分析
  • DMIオピニオン

第6章 COVID-19分析

第7章 タイプ別

  • 免疫グロブリンG（IgG）
    • IgG1
    • IgG2
    • IgG3
    • IgG4
  • 免疫グロブリンM（IgM）
  • 免疫グロブリンA（IgA）
    • IgA1
    • IgA2
  • 免疫グロブリンD（IgD）
  • 免疫グロブリンE（IgE）

第8章 形態別

  • 可溶性免疫グロブリン
  • 膜結合型免疫グロブリン

第9章 用途別

  • 低ガンマグロブリン血症
  • 慢性炎症性脱髄性多発神経炎
  • 免疫不全症
  • 重症筋無力症
  • 特発性血小板減少性紫斑病
  • 炎症性ミオパチー
  • その他

第10章 投与経路別

  • 静脈内投与
  • 皮下投与
  • その他

第11章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 診断センター
  • 研究・学術センター
  • その他

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第13章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第14章 企業プロファイル

  • Takeda Pharmaceuticals Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • CSL Limited
  • Octapharma AG
  • Kedrion Biopharma Inc.
  • Grifols, S.A.
  • ADMA Biologics, Inc.
  • Pfizer Inc.
  • Kamada Pharmaceuticals
  • Cygnus Technologies
  • Emergent BioSolutions Canada Inc.

第15章 企業概要付録

目次
Product Code: PH7392

Overview

Immunoglobulins (Ig) which are also known as antibodies are the glycoproteins produced by plasma cells. B cells are instructed by specific immunogens, such as bacterial proteins, to differentiate into plasma cells, which are protein-making cells that participate in humoral immune responses against bacteria, viruses, fungi, parasites, cellular antigens, chemicals, and synthetic substances. The immunogen or antigen reacts with a B-cell receptor on the cell surface of B lymphocytes. A signal is produced that directs the activation of transcription factors to stimulate the synthesis of antibodies, which are highly specific for the immunogen that stimulated the B cell.

Moreover, the various immunoglobulins produced by plasma cells are classified by isotype, each differs in function and antigen responses primarily due to structure variability. The five major antibody classes that have been identified in placental mammals, they are IgA, IgD, IgE, IgG, and IgM. This classification is based on differences in amino acid sequence in the constant region of the antibody heavy chains. IgG and IgA are further grouped into subclasses based on additional small differences in the amino acid heavy chain sequences. These are used to treat many autoimmune and other chronic disorders.

Market Dynamics: Drivers

Increasing demand for innovative immunoglobulins

The increasing demand for innovative immunoglobulins is expected to drive the market over the forecast period. The innovative immunoglobulins are mainly designed to treat various types of diseases and they aim to address the unmet needs associated with the management and treatment of various disorders by providing alternative or complementary treatment options. Regulatory approvals such as FDA approvals are also increasing, which further increases the adoption of immunoglobulins.

For instance, on May 19, 2023, AbbVie, cleared that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapies. EPKINLY is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology.

Moreover, immunoglobulins have traditionally been used for conditions such as primary immunodeficiency disorders and autoimmune diseases. However, researchers and pharmaceutical companies are focussing on exploring their potential for treating and diagnosing a broader range of conditions by using immunoglobulins.

For instance, on August 24, 2023, Thermo Fisher Scientific, the world leader in serving science, launched the EXENT Solution, after receiving IVDR certification. The EXENT solution is a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. The analyzer is combined with the EXENT Immunoglobulin Isotypes (GAM) immunoassay, a highly sensitive and specific immunoassay for measuring and quantifying IgG, IgA, and IgM.

Additionally, on March 29, 2022, Sanofi partnered with IGM Biosciences to create, develop, manufacture and commercialize six immunoglobulin M (IgM) antibody agonists, three against oncology targets and the other three against immunology/inflammation targets.

Further, the increasing prevalence of immunodeficiency and other immune-related disorders, rising FDA approvals, increasing clinical trials, increasing awareness and advancements in the development of novel products are the factors expected to drive the market over the forecast period.

Restraints

Factors such as severe and rare side effects of immunoglobulins like transfusion-related acute lung injury (TRALI), acute renal failure, anaphylaxis to IgE or IgG antibodies to IgA, arrhythmias, aseptic meningitis, arthritis, hepatitis, pleural effusion and other dermatological manifestations are expected to hamper the market.

Segment Analysis

The global immunoglobulin market is segmented based on type, form, application, route of administration, end-user and region.

The immunoglobulin G (IgG) segment accounted for approximately 52.1% of the immunoglobulin market share

The immunoglobulin G (IgG) segment is expected to hold the largest market share over the forecast period. Immunoglobulin G is further subdivided into four types, they are IgG1, IgG2, IgG3 and IgG4. IgG is the most commonly abundant class of antibodies in the human body, constituting about 75-80% of the total immunoglobulin pool. It is found in the blood and tissues and is crucial for long-term immunity. IgG can neutralize toxins and viruses, preventing them from infecting cells.

Furthermore, intravenous immunoglobulins involve the administration of IgG antibodies extracted from the plasma of thousands of donors. These intravenous immunoglobulins are used to boost the immune system in patients with immunodeficiency disorders and to modulate immune responses in certain autoimmune conditions.

For instance, on September 21, 2023, Biotest AG launched its intravenous immunoglobulin Yimmugo (IgG Next Generation) and got approval in the United Kingdom for the treatment of patients with congenital and acquired immunodeficiencies and for immunomodulation, following approvals in Germany and Austria.

Additionally, on January 6, 2023, Eisai Co., Ltd. And Biogen Inc. released the approval from U.S. Food and Drug Administration (FDA) for lecanemab-irmb (LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (AB) for the treatment of Alzheimer's disease (AD).

Geographical Analysis

North America accounted for approximately 41.1% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing adoption of immunoglobulins. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and biotechnology companies. The presence of major players actively performing research activities to develop immunoglobulin products for the treatment of various diseases.

For instance, on April 11, 2023, Takeda cleared that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application to expand the use of HYQVIA to treat primary immunodeficiency (PI) in children 2-16 years old. HYQVIA is the only subcutaneous immune globulin infusion that can be administered once a month, every three or four weeks and was first approved in the U.S. for the treatment of PI in adults.

Furthermore, the increasing adoption of immunoglobulins in the region is also driving the market in the region. There is a continuously increasing prevalence of immunodeficiency disorders in the region, further increasing the adoption of immunoglobulins for the treatment and management of these disorders. For instance, according to the Journal of Allergy and Clinical Immunology (JACI), 2020, the prevalence of primary immunodeficiency disorders in the United States is estimated at 1 in 2000 individuals.

Competitive Landscape

The major global players in the immunoglobulin market include: Takeda Pharmaceuticals Inc., CSL Limited, Octapharma AG, Kedrion Biopharma Inc., Grifols, S.A., ADMA Biologics, Inc., Pfizer Inc., Kamada Pharmaceuticals, Cygnus Technologies and Emergent BioSolutions Canada Inc. among others.

Key Developments

  • On September 26, 2023, Takeda released that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency or secondary immunodeficiency.
  • On February 18, 2021, Agilent Technologies Inc. launched the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma. The kit, which marks Agilent's entrance into SARS-CoV-2 testing in the US, has completed the notification process to the FDA in accordance with Section IV.D of FDA's "Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency".
  • On November 10, 2020, Beckman Coulter, a clinical diagnostics leader, launched its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE Mark. The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 100% sensitivity at >18 days post-symptom onset and positive PCR. Beckman Coulter's antibody assays and its other planned SARS-CoV-2 offerings run on the organization's award-winning immunoassay analyzers, including the DxI 800 high-throughput analyzer, which is capable of processing 200 samples per hour.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global immunoglobulin market. When infected with COVID-19, patients produce antibodies to fight off the infection. These antibodies are known as immunoglobulins and are key players in the response to COVID-19. The demand for immunoglobulins has increased due to the pandemic.

For instance, on May 21, 2021, the Defence Institute of Physiology and Allied Sciences (DIPAS), a laboratory of the Defence Research and Development Organisation (DRDO), developed an antibody detection-based kit 'DIPCOVAN', the DIPAS-VDx COVID-19 IgG Antibody Microwell ELISA for sero-surveillance. The DIPCOVAN kit can detect both spikes as well as nucleocapsid (S&N) proteins of SARS-CoV-2 virus with a high sensitivity of 97 percent and specificity of 99 percent.

Market Segmentation

By Type

  • Immunoglobulin G (IgG)
    • IgG1
    • IgG2
    • IgG3
    • IgG4
  • Immunoglobulin M (IgM)
  • Immunoglobulin A (IgA)
    • IgA1
    • IgA2
  • Immunoglobulin D (IgD)
  • Immunoglobulin E (IgE)

By Form

  • Soluble Immunoglobulins
  • Membrane-Bound Immunoglobulins

By Application

  • Hypogammaglobulinemia
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Immunodeficiency Disorders
  • Myasthenia Gravis
  • Idiopathic Thrombocytopenic Purpura
  • Inflammatory Myopathies
  • Others

By Route of Administration

  • Intravenous
  • Subcutaneous
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Research and Academic Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global immunoglobulin market segmentation based on type, form, application, route of administration, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of immunoglobulin market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global immunoglobulin market report would provide approximately 77 tables, 84 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Form
  • 3.3. Snippet by Application
  • 3.4. Snippet by Route of Administration
  • 3.5. Snippet by End-User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Innovative Immunoglobulins
    • 4.1.2. Restraints
      • 4.1.2.1. Severe Side Effects of Immunoglobulins
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. Patent Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Immunoglobulin G (IgG)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. IgG1
    • 7.2.4. IgG2
    • 7.2.5. IgG3
    • 7.2.6. IgG4
  • 7.3. Immunoglobulin M (IgM)
  • 7.4. Immunoglobulin A (IgA)
    • 7.4.1. IgA1
    • 7.4.2. IgA2
  • 7.5. Immunoglobulin D (IgD)
  • 7.6. Immunoglobulin E (IgE)

8. By Form

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 8.1.2. Market Attractiveness Index, By Form
  • 8.2. Soluble Immunoglobulins*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Membrane-Bound Immunoglobulins

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Hypogammaglobulinemia*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Chronic Inflammatory Demyelinating Polyneuropathy
  • 9.4. Immunodeficiency Disorders
  • 9.5. Myasthenia Gravis
  • 9.6. Idiopathic Thrombocytopenic Purpura
  • 9.7. Inflammatory Myopathies
  • 9.8. Others

10. By Route of Administration

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.1.2. Market Attractiveness Index, By Route of Administration
  • 10.2. Intravenous*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Subcutaneous
  • 10.4. Others

11. By End-User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.1.2. Market Attractiveness Index, By End-User
  • 11.2. Hospitals*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Specialty Clinics
  • 11.4. Diagnostic Centers
  • 11.5. Research and Academic Centers
  • 11.6. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. UK
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Takeda Pharmaceuticals Inc.*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. CSL Limited
  • 14.3. Octapharma AG
  • 14.4. Kedrion Biopharma Inc.
  • 14.5. Grifols, S.A.
  • 14.6. ADMA Biologics, Inc.
  • 14.7. Pfizer Inc.
  • 14.8. Kamada Pharmaceuticals
  • 14.9. Cygnus Technologies
  • 14.10. Emergent BioSolutions Canada Inc.

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us